Loading...
APTX logo

Aptinyx Inc.OTCPK:APTX Stock Report

Market Cap US$6.5m
Share Price
n/a
My Fair Value
n/a
1Y-73.4%
7D10.9%
1D
Portfolio Value
​
View

Aptinyx Inc.

OTCPK:APTX Stock Report

Market Cap: US$6.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aptinyx (APTX) Stock Overview

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. More details

APTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Earnings have declined by 10.2% per year over past 5 years

Does not have a meaningful market cap ($7M)

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

+ 1 more risk

APTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Aptinyx Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptinyx
Historical stock prices
Current Share PriceUS$0.096
52 Week HighUS$0.72
52 Week LowUS$0.009
Beta1.22
1 Month Change46.12%
3 Month Change43.07%
1 Year Change-73.43%
3 Year Change-97.32%
5 Year Change-99.48%
Change since IPO-99.52%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 12

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aptinyx (NASDAQ:APTX) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in ~300 patients with fibromyalgia — a disorder that causes widespread musculoskeletal pain. The main goal was the change from baseline in average daily pain as reported on the 0-to-10 numeric rating scale (NRS) during week 12 of the study. The company said that both doses did not show statistically significant separation from placebo. Patients on NYX-2925 at both doses showed a trend toward clinically meaningful improvement in pain, and some secondary goals, versus placebo by week 4. However, by week 12, the placebo group improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful, Aptinyx said in an Aug. 12 press release. NYX-2925 was well tolerated in the study, and no concerning safety issues were seen, according to the company. Aptinyx added that detailed data from the study continue to be evaluated.
Analysis Article • Aug 18

We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 21

Aptinyx: CNS Drug Discoverer With Depressed Price

APTX stock went into long-term depression following a failed trial in 2019. However, the company has continued progressing its oral NMDA receptor modulator in the same indication, in a subgroup. The company has a decent amount of cash.
Analysis Article • Apr 13

Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 09

Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

Aptinyx Inc. ( NASDAQ:APTX ) shareholders might be concerned after seeing the share price drop 21% in the last month...
Analysis Article • Jan 30

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

The big shareholder groups in Aptinyx Inc. ( NASDAQ:APTX ) have power over the company. Generally speaking, as a...
Analysis Article • Dec 26

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Analysis Article • Nov 27

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Aptinyx Inc. (NASDAQ:APTX) shareholders should be happy to see the share price up 15% in the last month. But that is...

Shareholder Returns

APTXUS BiotechsUS Market
7D10.9%1.2%1.1%
1Y-73.4%34.6%28.7%

Return vs Industry: APTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: APTX underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is APTX's price volatile compared to industry and market?
APTX volatility
APTX Average Weekly Movement19.1%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: APTX's share price has been volatile over the past 3 months.

Volatility Over Time: APTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201512Craig Jalbertwww.aptinyx.com

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc.

Aptinyx Inc. Fundamentals Summary

How do Aptinyx's earnings and revenue compare to its market cap?
APTX fundamental statistics
Market capUS$6.50m
Earnings (TTM)-US$66.09m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.1x
P/E Ratio

Is APTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$35.74m
Gross Profit-US$35.74m
Other ExpensesUS$30.35m
Earnings-US$66.09m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.98
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio137.5%

How did APTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/03 16:19
End of Day Share Price 2023/12/29 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptinyx Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.